CURRICULUM VITAE

Peter I. Karachunski, M.D.

PROFESSIONAL ADDRESS

University of Minnesota
Department of Neurology
420 Delaware ST SE
Campus Mail Code: 295 MAYO
Minneapolis, MN 55455
Phone (612) 626-2499
Fax (612) 301-1455
E-mail: karac001@umn.edu

IDENTIFYING INFORMATION

Education

Degree	Institution	Date Degree Granted
M.D.	State Medical University, Moscow, Russia	1987
Residency Pediatric Neurology	1st Children's Hospital, Moscow	1987-1989
Residency Pediatrics	University of Minnesota	2000-2002
Residency Pediatric Neurology	University of Minnesota	2002-2005
Fellow Clinical Neurophysiology	University of Minnesota	2005-2006
MDA Fellow, Clinical Research and Neuromuscular Medicine	University of Minnesota	2006-2008

Certifications, Licenses

American Board of Psychiatry and Neurology, Neuromuscular Medicine	2008-present
American Board of Psychiatry and Neurology, Child Neurology	2006-present
Medical Physician and Surgeon, Minnesota	2005-present
DEA Controlled Substance Registration Certificate	2005-present

Academic Appointments

University of Minnesota Medical School, Twin Cities campus, Department of Assistant Professor	2008-present
Pediatric Neurology, 7th Children's Hospital, Moscow, Russia	1989-1991

Academic Administrative Appointments

Clinical Director, Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota	2011-present
Interim Director, Pediatric Neurology, University of Minnesota Medical Center, Fairview-Amplatz Children's Hospital	2011-2013

Training

MDA Fellow, Clinical Research and Neuromuscular, Department of Neurology, University of Minnesota	07/2006 - 06/2008
Fellow, Clinical Neurophysiology, Department of Neurology, University of Minnesota	07/2005 - 06/2006
Resident, Pediatric Neurology, University of Minnesota	07/2002 - 0 6/ 2005
Resident, Department of Pediatrics, University of Minnesota	06/2000 - 06/2002
Resident, Department of Pediatric Neurology, 1st Children's Hospital, Moscow	09/1987 - 09/1989

Research Training

Post-doctoral Fellow, Department of Biochemistry, Biophysics and Molecular Biology, University of Minnesota	06/1993 - 05/2000
Pre- doctoral Fellow, Department of Biochemistry, Biophysics and Molecular Biology, University of Minnesota	02/1991 - 05/1993

Clinical/Hospital Appointments

Clinical Director, Muscular Dystrophy Association Clinic, Fairview University Medical Center, Minneapolis	2011-present
Clinical Director, Muscular Dystrophy Association Clinic, Gillette Children's Specialty Healthcare, St. Paul, MN	2011- February 2015
Staff Physician, Masonic Children's Hospital, Department of Neurology, University of Minnesota	2010-present
Staff Physician, Muscular Dystrophy Clinic Fairview University of Minnesota	2008- present
Physician Volunteer, MDA Summer Camp, MN Chapter	2008- present
Staff Physician, Gillette Lifetime Clinic, St. Paul, MN	2010- February 2015
Staff Physician, Neuromuscular Clinic, Gillette Pediatric Specialty Care	2008- February 2015

Consulting Positions

Neuromuscular Consultant, MDA Minnesota Chapter St. Paul, Minnesota	2012-present
Consultant, Paul and Sheila Wellstone Muscular Dystrophy Center Marzolf Symposium, University of Minnesota	2012-present
Clinical Consultant, Muscular Dystrophy Association, Minnesota Chapter Board Member	2011-present
Neurology Residency Clinical Competency Committee (NRCCC), Member, Department of Neurology, University of Minnesota	2011-present
Clinical Consultant, Gillette Children's Specialty Healthcare SMA Conference, Bloomington, MN	2012
Clinical Consultant, Gillette Children's Specialty Healthcare Third Biennial Pediatric Neurosciences Conference, Minneapolis, MN	2012

Current Membership and Offices in Professional Organizations

American Academy of Neurology	2005-present
Child Neurology Society	2005-present
International World Muscle Society	2012-present

HONORS AND AWARDS FOR RESEARCH WORK, TEACHING, PUBLIC ENGAGEMENT, AND SERVICE

External Sources

Masonic Mission Award, Nomination (1 of 26)	04/14/2016
Masonic Mission Award, Nomination (1 of 18)	10/13/2016
Muscular Dystrophy Association Humanitarian Award	2011
Muscular Dystrophy Association	2006-2008
Clinical Research Training Grant and Neuromuscular Fellowship	

RESEARCH AND SCHOLARSHIP

Grants and Contracts

External Sources

A. Principal Investigator

1. (CON63541/00060071)
   Role: PI
   Grant Award Number 492691
   Muscular Dystrophy Association (MDA)
   Title: MDA Clinic Grant, University of MN Clinic
   01/01/17 – 12/31/2019
   Direct Costs per year $25,000
   Effort: 0%

B. Co-Investigator

1. (CON54271/00049514)
   Role: Co-I
   Award Number B5161002
   Pfizer, Inc.
   A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Ambulatory Boys with Duchene Muscular Dystrophy
   02/13/15 – 02/28/18
   Direct Costs per Year / Clinical Trial:
   Total Direct to Date – $59,197
   Maximum Allowed – $206,228
   Effort: 1%

2. (CON43355/00037328)
   Role: Co-I
   PTC- PTC124 for DMD
   PTC Therapeutics, Inc.
   Protocol No. PTC124 GD 020 DMD entitled, A Phase 3 Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Dystrophinopathy
   04/01/13 – 12/31/17
   Direct Costs per Year / Clinical Trial:
   Total Direct to Date – $38,378
   Maximum Allowed – $38,378
   Effort: 0%

3. (CON29120/00021378)
   Role: Co-I
   PTC124-GD-016-DMD
   PTC Therapeutics, Inc.

An Open-Label, Safety Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy
03/01/08 – 02/26/18
Direct Costs per Year / Clinical Trial:
Total Direct to Date – $71,522
Maximum Allowed – $71,522
Effort: 1%

4. (CON53694/00048897)
Role: Co-I
PI: Gerald Raymond
Award Number 4658-301
Sarepta Therapeutics, Inc.
An Open-Label, Multi-Center, 48-Week Study With A Concurrent Untreated Control Arm To Evaluate The Efficacy And Safety Of Eteplirsen In Duchenne Muscular Dystrophy
10/01/14 – 09/30/17
Direct Costs per Year / Clinical Trial:
Total Direct to Date – $123,774
Maximum Allowed – $244,812
Effort: 1%

5. (CON60886/00058590)
Role: Co-I
PI: Kyriakie Sarafoglou
Alexion Pharmaceuticals
Hypophosphotasemia in Duchenne muscular Dystrophy
03/01/2016-03/01/2020
Direct Costs per Year / Clinical Trial:
Total Direct to Date – $230,346
Maximum Allowed – $323,828
Effort: 5%

6. (CON52499/00047588)
Role: Co-I
PI: Kyba, Michael
NIAMS-National Institute of Arthritis
07/15/2015-06/30/2020
Direct Costs Per Year: $220,000
Effort: 4%

7. (CON41494/00035313)
Role: Co-I
PI: Manousakis
For NIH/NIAMS 1P50AR060836
CINRG
Becker Muscular Dystrophy – A Natural History Study to Predict the Efficacy of Exon Skipping
05/11/2016-05/10/2017
Direct Costs Per Year: $1700
Effort: 0%

New, Not Yet Started

1.
Role: Co-I
PI: Michael Kyba
R01 AR055685-01A1
NIH

Molecular pathways by DUX4, an FSHD-associated gene
03/19/10 – 02/28/15

2.
Role: Co-I
PI: Manousakis
Acceleron – FSHD Study
A Phase 2 Randomized

3.
Role: Co-I
PI: Manousakis
Italfarmaco – DMD Study

Completed Research Support

1.
Role: Co-PI
PI: Gerald Raymond
DMD115501 PO# 43100432
BioMarin Pharmaceutical Inc. (Prosensa)
DMD115501-An open-label extension study of the long-term safety, tolerability and efficacy of drisapersen in US and Canadian subjects with Duchenne Muscular Dystrophy.
09/01/14 – 10/30/16

2.
Role: PI
1P50AR060836
NIH / NIAMS
Center for Research Translation of Systemic Exon-Skipping in Muscular Dystrophy
09/01/12 – 08/31/16

3.
Role: PI
Award Number Not Provided
FSH Society
A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life for Pediatric Facioscapulohumeral Muscular Dystrophy
12/01/13 - 05/28/15

4.
Role: PI
1R01AR061875
NIH / NIAMS
Clinical Meaningful Outcomes for Duchenne Muscular Dystrophy Therapeutic Trials
09/01/12 – 08/31/15

5.
Role: PI
1R01AR062380
NIH / NIAMS
Biomarkers Discovery and Validation in DMD Nat History
09/01/12- 07/30/15

6.
Role: PI
Clinical Translational Research Services (CTRS),

New tools used to study effects of growth hormone therapy on bone health and muscle function in boys with Duchenne muscular dystrophy,"
7/1/2014-6/31/2015

7.
Role: PI
Frank J & Eleanor A Maslowski Charitable Trust
Bone Heath in Duchene Muscular Dystrophy
01/01/12 - 09/30/14

8.
Role: PI – Core B
P30-AR057220
NIH / NIAMS
Muscular Dystrophy Center Core Laboratories
08/01/09 – 06/30/14

9.
Role: PI
DMD Cardiac Study
MDA
Cardiac Natural History in DMD
06/01/09 - 05/31/12

10.
Role: PI
DMD Young Patient Study
MDA
Outcome measures in young DMD boys
06/01/09 - 05/31/12

11.
Role: PI
DMD114876
GSK2402968
An exploratory study to assess two doses of GSK2402968 in the Treatment of Ambulant boys with Duchenne Muscular Dystrophy
09/01/2011 – 04/30/2013

12.
Role: Co-Investigator
PI: John W Day
R01-NS056592
NIH / NINDS
Structural and Functional CNS Changes in Myotonic Dystrophy Types 1 and 2
04/01/07 - 03/31/12

13.
Role: Co-I – Project 3
PI: Laura A Ranum
P01-NS058901-01A1
NIH
Myotonic Dystrophy: Molecular Pathophysiology and CNS Effects
Project 3 (PI, Day)
Structural and Functional CNS Changes in Children with Myotonic Dystrophy
04/01/08 - 03/31/13

14.
Role: Co-I
PI: John W Day
IPLEX for DM1
A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints after Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults with Myotonic Dystrophy Type 1
03/01/08 - 02/28/10

15.
Role: PI
UCD0305
CINRG
A Longitudinal Study of the Relationship between Impairment, Activity Limitation, Participation and Quality of Life in Persons with Confirmed DMD
01/01/07 - 12/31/11

University Sources
Role: PI
Grant Number not applicable
Clinical Translational Research Services
New tools used to study effects of growth hormone therapy on bone health and muscle function in boys with Duchenne muscular dystrophy
06/04/14-06/04/15

Publications [Note if these are published electronically with a URL, provided if appropriate]

h-index	*h(f)*-index	Total Publications	First/Last Author Publications	Total Citations	First/Last Author Citations
14	*5*	*30*	*9*	*695*	*226*

1. Foster LA, Johnson MR, MacDonald JT, **Karachunski PI**, Henry TR, Nascene DR, Moran BP, Raymond GV. Infantile Epileptic Encephalopathy Associated With SCN2A Mutation Responsive to Oral Mexiletine. Pediatr Neurol. 2017 Jan:66: 108-111.
    - Impact Factor: 1.866
    - Citation Index: 0
    - Candidate contributions: editing and review, Data acquisition

2. Petryk A, Polgreen LE, Grames M, Lowe DA, Hodges JS, **Karachunski PI**. Feasibility and tolerability of low-intensity whole body vibration and its effects on muscle function and bone in patients with dystrophinopathies: A pilot study. Muscle Nerve. 2017 Feb 6.
    - Impact Factor: 2.713
    - Citation Index: 0
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

3. Bello L, Flanigan KM, Weiss RB; United Dystrophinopathy Project., Spitali P, Aartsma-Rus A, Muntoni F, Zaharieva I, Ferlini A, Mercuri E, Tuffery-Giraud S, Claustres M, Straub V, Lochmüller H, Barp A, Vianello S, Pegoraro E, Punetha J, Gordish-Dressman H, Giri M, McDonald CM, Hoffman EP; Cooperative International Neuromuscular Research Group. Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. Am J Hum Genet. 2016 Nov 3;99(5):1163-1171. doi: 10.1016/j.ajhg.2016.08.023
    - Impact Factor: 10.794
    - Citation Index: 2
    - Candidate contributions: editing and review, Data acquisition

4. Connolly AM, Florence JM, Zaidman CM, Golumbek PT, Mendell JR, Flanigan KM, **Karachunski PI**, Day JW, McDonald CM, Darras BT, Kang PB, Siener CA, Gadeken RK, Anand P, Schierbecker JR, Malkus EC, Lowes LP, Alfano LN, Johnson L , Nicorici A, Kelecic JM, Quigley J, Pasternak AE, Miller JP, MDA DMD Clinical Research Network; Clinical Trial Readiness in non-Ambulatory Boys and Men with Duchenne muscular dystrophy: MDA-DMD Network Follow-up. Muscle Nerve. 2016 Accepted Article. 1-40. doi: 10.1002/mus.25089.
    - Impact Factor: 2.713
    - Citation Index: 1
    - Candidate contributions: editing and review, Data acquisition

5. Takamura K, Dalton, J, **Karachunski PI**. Congenital fiber type disproportion myopathy and novel compound heterozygous mutations in the RYR1 gene. Next generation sequencing-A first line diagnostic tool for congenital myopathy. Neuromuscul Disord. 2016 Oct;26(2):S137.
    - Impact Factor: 3.107
    - Citation Index: 0
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

6. Foster LA, Johnson MR, MacDonald JT**, Karachunski PI**, Henry TR, Nascene DR, Moran BP, Raymond GV. Infantile Epileptic Encephalopathy Associated With SCN2A Mutation Responsive to Oral Mexiletine. Pediatr Neurol. 2016 Oct 18.
    - Impact Factor: 1.866
    - Citation Index: 2
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

7. Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S; CINRG investigators. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016 Jul 26;87(4):401-9.
    - Impact Factor: 8.166
    - Citation Index: 3
    - Candidate contributions: editing and review, Data acquisition

8. Petrovski S, Küry S, Myers CT, Anyane-Yeboa K, Cogné B, Bialer M, Xia F, Hemati P, Riviello J, Mehaffey M, Besnard T, Becraft E, Wadley A, Politi AR, Colombo S, Zhu X, Ren Z, Andrews I, Dudding-Byth T, Schneider AL, Wallace G; University of Washington Center for Mendelian Genomics., Rosen AB, Schelley S, Enns GM, Corre P, Dalton J, Mercier S, Latypova X, Schmitt S, Guzman E, Moore C, Bier L, Heinzen EL, **Karachunski PI**, Shur N, Grebe T, Basinger A, Nguyen JM, Bézieau S, Wierenga K, Bernstein JA, Scheffer IE, Rosenfeld JA, Mefford HC, Isidor B, Goldstein DB. Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. Am J Hum Genet. 2016 May 5;98(5):1001-10.
    - Impact Factor: 10.794
    - Citation Index: 5
    - Candidate contributions: editing and review, Data acquisition

9. Connolly AM, Florence JM, Zaidman CM, Golumbek PT, Mendell JR, Flanigan KM, **Karachunski PI**, Day JW, McDonald CM, Darras BT, Kang PB, Siener CA, Gadeken RK, Anand P, Schierbecker JR, Malkus EC, Lowes LP, Alfano LN, Johnson L , Nicorici A, Kelecic JM, Quigley J, Pasternak AE, Miller JP, MDA DMD Clinical Research Network; Clinical Trial Readiness in non-Ambulatory Boys and Men with DMD: MDA-DMD Network Follow-up. Twelve and 24-month outcomes in DMD. Muscle Nerve. 2016 Accepted Article. 1-40. doi: 10.1002/mus.25089.
    - Impact Factor: 2.713
    - Citation Index: 1
    - Candidate contributions: editing and review, Data acquisition

10. Hamdoun E, **Karachunski PI**, Nathan B, Fischer M, Torkelson JL, Drilling A, Petryk A. Case Report: The Specter of Untreated Congenital Hypothyroidism in Immigrant Families. Pediatrics. 2016 May;137(5):e1-8. doi: 10.1542/peds.2015-3418
    - Impact Factor: 5.196
    - Citation Index: 0
    - Candidate contributions: manuscript preparation, editing and review, Data acquisition

11. Petryk A, Polgreen LE, Marsh J, Lowe DA, Hodges JS, **Karachunski P**. Tolerability and feasibility of whole body vibration and its effects on muscle function and bone in patients with dystrophinopathies. Horm.Resear.Pardi. 2016 86:166-167.
    - Impact Factor: 1.661
    - Citation Index:
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

12. **Karachunski PI**, Dalton, J, Marsh J. Muscle Ultrasound in Duchenne muscular dystrophy: Useful tool to monitor progression of early disease. Neuromuscul Disord. 2015 Oct;25(2):S197.
    - Impact Factor: 3.107
    - Citation Index: 0
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

13. Connolly AM, Malkus EC, Mendell JR, Flanigan KM, Miller JP, Schierbecker JR, Siener CA, Golumbek PT, Zaidman CM, McDonald CM, Johnson L, Nicorici A, **Karachunski PI**, Day JW, Kelecic JM, Lowes LP, Alfano LN, Darras BT, Kang PB, Quigley J, Pasternak AE, Florence JM; MDA DMD Clinical Research Network. Outcome reliability in non-Ambulatory Boys/Men with Duchenne muscular dystrophy. Muscle Nerve. 2015 Apr;51(4):522-32. doi: 10.1002/mus.24346. Epub 2015 Feb 11. PubMed PMID: 25056178; PubMed Central PMCID: PMC4305351.
    - Impact Factor: 2.713
    - Citation Index: 7
    - Candidate contributions: editing and review, Data acquisition

14. Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'donnell MW, Peltz SW, Mcdonald CM; PTC124-GD-007-DMD STUDY GROUP. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014 Oct;50(4):477-87. doi: 10.1002/mus.24332. PubMed PMID: 25042182; PubMed Central PMCID: PMC4241581.
    - Impact Factor: 2.713
    - Citation Index: 67
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

15. Mah JK, Chen YW, Duong T, Cnaan A, Sund Z, Morgenroth LP, McDonald C, Tulinius M, Sparks S, Webster R, Connolly A, **Karachunski PI**, Clemens PR. Baseline characteristics of the CINRG infantile facioscapulohumeral muscular dystrophy (FSHD) cohort. Neuromuscul Disord. 2014 Oct;24(9-10):798.
    - Impact Factor: 3.107
    - Citation Index: 0
    - Candidate contributions: Data acquisition

16. Connolly AM, Florence JM, Zaidman CM, Golumbek PT, Mendell JR, Flanigan KM, **Karachunski PI**, Day JW, McDonald CM, Darras BT, Kang PB, Siener CA, Gadeken RK, Anand P, Schierbecker

JR, Malkus EC, Lowes LP, Alfano LN, Johnson L , Nicorici A, Kelecic JM, Quigley J, Pasternak AE, Miller JP, MDA DMD Clinical Research Network; Clinical Trial Readiness in non-Ambulatory Boys and Men with Duchene muscular dystrophy: 12 and 24-month follow-up from the MDA-DMD Network. Neuromuscul Disord. 2014 Oct;24(9-10):855-856.

- Impact Factor: 3.107
- Citation Index: 0
- Candidate contributions: editing and review, Data acquisition

17. Connolly AM, Florence JM, Cradock MM, Eagle M, Flanigan KM, McDonald CM, **Karachunski PI**, Darras BT, Bushby K, Malkus EC, Golumbek PT, Zaidman CM, Miller JP, Mendell JR; MDA DMD Clinical Research Network. One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. Pediatr Neurol. 2014 Jun;50(6):557-63. doi: 10.1016/j.pediatrneurol.2014.02.006. Epub 2014 Feb 15. PubMed PMID: 24842254;PubMed Central PMCID: PMC4197452.
    - Impact Factor: 1.866
    - Citation Index: 5
    - Candidate contributions: editing and review, Data acquisition

18. Connolly AM, Florence JM, Cradock MM, Eagle M, Flanigan KM, McDonald CM, **Karachunski PI**, Darras BT, Bushby K, Malkus EC, Golumbek PT, Zaidman CM, Miller JP, Mendell JR; MDA DMD Clinical Research Network. One year outcome of boys with DMD using the Bayley-III scales of infant and toddler development. Neuromuscul Disord. 2013 Oct;23(9-10):778.
    - Impact Factor: 3.107
    - Citation Index: 0
    - Candidate contributions: editing and review, Data acquisition

19. Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA, Wulf CO, Anand P, Golumbek PT, Zaidman CM, Philip Miller J, Lowes LP, Alfano LN, Viollet-Callendret L, Flanigan KM, Mendell JR, McDonald CM, Goude E, Johnson L, Nicorici A, **Karachunski PI**, Day JW, Dalton JC, Farber JM, Buser KK, Darras BT, Kang PB, Riley SO, Shriber E, Parad R, Bushby K, Eagle M; MDA DMD Clinical Research Network. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord. 2013 Jul;23(7):529-39. doi: 10.1016/j.nmd.2013.04.005. Epub 2013 May 28. PubMed PMID: 23726376; PubMed Central PMCID: PMC3743677.
    - Impact Factor: 3.107
    - Citation Index: 18
    - Candidate contributions: editing and review, Data acquisition

20. Utz J, Ziegler R, Ahmed A, Nestrasil I, **Karachunski PI**, Bothun E, Diethelm-Okita, B, Whitley, CB. Combination oral therapy for lysosomal gangliosidoses using FDA approved medications. Mole. Genet.Metab. 2012;108 (2);S94.
    - Impact Factor: 3.093
    - Citation Index: 0
    - Candidate contributions: Data acquisition

21. Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA, Wulf CO, Anand P, Golumbek PT, Zaidman CM, Philip Miller J, Lowes LP, Alfano LN, Viollet-Callendret L, Flanigan KM, Mendell JR, McDonald CM, Goude E, Johnson L, Nicorici A, **Karachunski PI**, Day JW, Dalton JC, Farber JM, Buser KK, Darras BT, Kang PB, Riley SO, Shriber E, Parad R, Bushby K, Eagle M; MDA DMD Clinical Research Network. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuro. 2012;78:1.
    - Impact Factor: 8.166
    - Citation Index: 0

- Candidate contributions: editing and review, Data acquisition

22. Florence JM, Connolly AM, Miller JP, Malkus E, Schierbecker JR, Siener C, Wulf C, Anand P, McDonald CM, Goude E, Johnson L, Nicorici A, **Karachunski PI**, Day JW, Dalton J, Kelecic J, Paulson K, Naughton C, Lowes L, Alfano L, Viollet-Callendret L, Flanigan K, Mendell, J, Darras B, Quigley J, Pasternak A, Shriber E, Parad R, MDA DMD Clinical Research Network; Outcomes Measure Reliability in Non Ambulatory Boys and Men with Duchenne Muscular Dystrophy (DMD): Results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuro. 2012. 78:S1.
    - Impact Factor: 8.166
    - Citation Index: 0
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

23. **Karachunski PI**, Clark, HB , Dalton, J. Syndrome of pontobulbar palsy and sensorineural deafness (Brown-Vialetto-van Laere syndrome) in two sisters: detailed neurophysiological and neuropathological analysis . Annals of Neurology. 2011: 70: S146.
    - Impact Factor: 9.638
    - Citation Index: 1
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

24. Bjoraker, K, Eisengart, J, **Karachunski, PI**, Oz, G, Whitley, C. A natural history study of hexosaminidase deficiency. *Mole. Gen.Metob.. 99(2): S11*.
    - Impact Factor: 3.093
    - Citation Index: 0
    - Candidate contributions: Data acquisition

25. **Karachunski PI**, Margolis, M , Dalton, J, Day, JW. LGMD 2l in Twin Brothers: Response to Prednisone. *Neuro.. 72(11): A304*.
    - Impact Factor: 8.166
    - Citation Index: 0
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

26. Day, JW, Margolis, JM , **Karachunski, PI**, Dalton, JC , Ranum, LPW; Familial Neuromyotonia in a five-generation kindred: A distinct phenotype due to a novel mutation in the potassium channel gene KCNA-1 . *Annals of Neurology* . 2007: 62: S5.
    - Impact Factor: 9.638
    - Citation Index: 0
    - Candidate contributions: manuscript preparation, editing and review, Data acquisition

27. Monfardini C., Milani M., Ostlie N., Wang W., **Karachunski PI,** Okita D.K., Lindstrom J., Conti-Fine B.M. Adoptive protection from experimental myasthenia gravis with T cells from mice treated nasally with acetylcholine receptor epitopes. *Journal of Neuroimmunology* .J23 (J - 2), J23-34, *2002 Feb.*
    - Impact Factor: 2.536
    - Citation Index: 12
    - Candidate contributions: Literature search, manuscript preparation, editing and review, Data acquisition

28. Ostlie N.S., **Karachunski PI**., Wang W., Monfardini C., Kronenberg M., Conti-Fine B.M. Transgenic expression of I L- 10 in T cells facilitates development of experimental myasthenia gravis. *Journal of Immunology*. J 66(8), 4853-62, *200J* Apr 15.
    - Impact Factor: 4.985

- Citation Index: 30
- Candidate contributions: Literature search, manuscript preparation, editing and review, Data acquisition

29. **Karachunski PI**., Ostlie N.S., Monfardini C., Conti-Fine B.M. Absence of IFN-gamma or I L-12 has different effects on experimental myasthenia gravis in C578L/6 mice. *Journal of Immunology. 164(10): 5236-44, 2000 May* 15.
    - Impact Factor: 4.985
    - Citation Index: 56
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

30. Wang Z- Y., **Karachunski PI**. , Howard Jr., J .F. and Conti-Fine B .M. 1999. Passive Myasthenia Gravis Induced in SCID mice by transfer of blood cells from myasthenic patients. Conference: International Workshop on Myasthenia Gravis Location: MYSORE, INDIA Date: NOV, 1998 Sponsor(s): Univ Texas Med Branch, Dept Microbiol & Immunol; Assoc Francaise Contre Les Myopathies; TEVA Pharmaceut; Crescent Healthcare Inc; Ultracare Home Hlth MYASTHENIA GRAVIS: DISEASE MECHANISM AND IMMUNOINTERVENTION Pages: 125-140 Published: 2000
    - Impact Factor:
    - Citation Index:
    - Candidate contributions: manuscript preparation, editing and review, Data acquisition

31. **Karachunski PI**. , Ostlie N. S., Okita D. K., and Conti-Fine B .M. 1999. Protective role of Th2 cells in mouse experimental myasthenia gravis. Conference: International Workshop on Myasthenia Gravis Location: MYSORE, INDIA Date: NOV, 1998 Sponsor(s): Univ Texas Med Branch, Dept Microbiol & Immunol; Assoc Francaise Contre Les Myopathies; TEVA Pharmaceut; Crescent Healthcare Inc; Ultracare Home Hlth MYASTHENIA GRAVIS: DISEASE MECHANISM AND IMMUNOINTERVENTION Pages: 161-172 Published: 2000
    - Impact Factor:
    - Citation Index:
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

32. **Karachunski PI**, Ostlie N. S. , Okita D. K., and Conti-Fine B .M. 1999. Interleukine - 4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of C04 + epitope sequences of the acetylcholine receptor. J. Neuroimmunol.95, 73- 84.
    - Impact Factor: 2.536
    - Citation Index: 32
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

33. Wang Z- Y., **Karachunski, PI**, Howard Jr., J., Conti-Fine B.M. 1999. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes. Role of C04+ and CD8+ cells. Neurology. 52: 484-497.
    - Impact Factor: 8.166
    - Citation Index: 28
    - Candidate contributions: Literature search, manuscript preparation, editing and review, Data acquisition

34. **Karachunski PI**. Ostlie N. S . , Okita D. K., Garman R. and Conti-Fine B .M. 1999. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents Experimental Myasthenia Gravis. J. Neuroimmunol. 93: 108 -121.
    - Impact Factor: 2.536
    - Citation Index: 28

- Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

35. Maus A. D. J., Pereira E. F. R., **Karachunski PI**, Macklin K., Horton R.M., Navaneetham D., Cortes W.S. , Albuquerque E. X. , and Conti-Fine B.M. 1998 . Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptor. Mol Pharnmacol .54: 779 - 788.
    - Impact Factor: 3.931
    - Citation Index: 162
    - Candidate contributions: manuscript preparation, editing and review, Data acquisition

36. Raju R. , Zhan , W- Z., **Karachunski PI**, Conti-Fine B .M., Sieck G.C. and S. David. 1998. Polymorphism at HLA DQ locus determines susceptibility to experimental autoimmune myasthenia gravis. J. Immunol. 160 : 4169- 4174
    - Impact Factor: 4.985
    - Citation Index: 24
    - Candidate contributions: Literature search, manuscript preparation, editing and review, Data acquisition

37. Conti-Fine B. M., Duraiswamy N. , **Karachunski PI**, Raju R. , Diethelm-Okita B. , Okita D. , Howard J . Jr. and Wang Z-Y. 1998 T-cell recognition of the acetylcholine receptor in myasthenia gravis. "Myasthenia gravis and related disorders." N.Y. Acad. Sci. 841:283- 308.
    - Impact Factor: 4.518
    - Citation Index: 19
    - Candidate contributions: editing and review, Data acquisition

38. Raju R., Zhan, W-Z., **Karachunski PI**, Sieck G.C., Conti-Fine B.M. and David S. 1998. Susceptibility of HLA DR3 transgenic mice to experimental autoimmune myasthenia gravis. "Myasthenia gravis and related disorders." N.Y .Acad. Sci. 841:360-364.
    - Impact Factor: 4.518
    - Citation Index: 2
    - Candidate contributions: editing and review, Data acquisition

39. **Karachunski PI**, Ostlie N.S., Lei S., Okita D.K., Lindstrom J .M. and Conti–Fine B .M. 1998. Immunization of bml2 mice with high doses of acetylcholine receptor overcomes their resistance to Experimental autoimmune Myasthenia Gravis. "Myasthenia gravis and related disorders." N. Y. Acad. Sci. 841: 555- 559.
    - Impact Factor: 4.518
    - Citation Index: 1
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

40. **Karachunski PI**., Ostlie N. S., Okita D. K. and Conti-Fine B.M. 1998. Nasal administration of synthetic acetylcholine receptor T epitopes affects the immune response of the acetylcholine receptor and prevents experimental myasthenia gravis. "Myasthenia gravis and related disorders." N. Y. Acad. Sci. 841: 560-564.
    - Impact Factor: 4.518
    - Citation Index: 2
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

41. **Karachunski PI**., Ostlie N., Okita D. K. and Conti–Fine B. M. 1997. Prevention of Experimental Autoimmune Myasthenia Gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J Clin. Invest. 100:3 027-303 5.
    - Impact Factor: 12.575
    - Citation Index: 76

- Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

42. Horton R. and **Karachunski PI**. 1996. Personalizing your Internet environment on a shared computer. BioTechniques 20: 996- 998.
    - Impact Factor: 2.298
    - Citation Index: 0
    - Candidate contributions: Literature search, manuscript preparation, editing and review

43. Horton R., **Karachunski PI**., and Conti-Fine B .M. 1995. PCR screening of transgenic RAG-2 "Knockout" Immunodeficient mice. BioTechniques 19: 690 - 691.
    - Impact Factor: 2.298
    - Citation Index: 11
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

44. Horton R., **Karachunski PI**., Kellermann S. and Conti–Fine B .M. 1995. Simple, Inexpensive, Computerized Rodent Activity Meters. BioTechniques 19: 594 - 597.
    - Impact Factor: 2.298
    - Citation Index: 7
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing and review, Data acquisition

45. **Karachunski PI**., Ostlie N., Bellone M., Infante A. J., and Conti-Fine B .M. 1995. Mechanism by which the I-Abm12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice. Scand. J. Immunol. 42, 215-225.
    - Impact Factor: 2.27
    - Citation Index: 28
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing, data acquisition

46. Bellone M., **Karachunski PI**., Ostlie N., Lei S., and Conti-Tronconi B .M. 1995. Clustering of T and B cell epitopes within short sequence regions of the nicotinic acetylcholine receptor. Scand. J. Immunol. 41:135-40.
    - Impact Factor: 2.27
    - Citation Index: 9
    - Candidate contributions: Literature search, manuscript preparation, editing

47. **Karachunski PI**., Ostlie N., Conti-Tronconi B.M., and Bell one M. 1994. Residues within the alpha-subunit sequence 304-322 of muscle acetylcholine receptor forming autoimmune CD 4+ epitopes in BALB/c mice. Immunology 82:22.
    - Impact Factor: 4.078
    - Citation Index: 2
    - Candidate contributions: Develop study concept and design, Literature search, manuscript preparation, editing

48. Bellone M., **Karachunski PI**., Ostlie N., Lei S., and Conti -Tronconi B.M. 1994. Preferential pairing of T and B cells for production of antibodies without covalent association of T and B epitopes. Eur. J. Immunol. 2 4: 799.
    - Impact Factor: 4.179
    - Citation Index: 19
    - Candidate contributions: Literature search, manuscript preparation, editing, data acquisition

49. Moiola L., **Karachunski PI**., Protti M. P., Howa r d Jr., J.F., and Conti-Tronconi B .M. 1994. Epitopes on the subunit of human muscle acetylcholine receptor recognized by CD4+ cell s of myasthenia gravis patients and healthy subjects. J. Clin. Invest. 93:1020
    - Impact Factor: 12.575
    - Citation Index: 54
    - Candidate contributions: Literature search, manuscript preparation, editing

50. Bellone M., Ostlie N., **Karachunski PI**., Lei S., and Conti-Tronconi B.M. 1993. Cryptic epitopes on the nicotinic acetylcholine receptor are recognized by autoreactive CD4+ cells. J. Immunol. 151:1025.
    - Impact Factor: 4.985
    - Citation Index: 21
    - Candidate contributions: manuscript preparation, editing, Data acquisition
51. Bellone M., Ostlie N., **Karachunski PI**., Lei S., and Conti-Tronconi B.M. 1993. Sensitization of C57BL/6 Mice Against Selected ACHR T-Epitopes Reveals Hidden B-Epitopes. J. Immunol. 150:A277.
    - Impact Factor: 4.985
    - Citation Index: 21
    - Candidate contributions: Data acquisition

Presentations

Invited Oral Presentations at International Professional Meetings, Conferences, etc.
Invited Oral Presentations at National Professional Meetings, Conferences, etc.
Invited Oral Presentations at Local and Regional Professional Meetings, Conferences, etc.
Peer-reviewed Oral Presentations at Professional Meetings, Conferences, etc.

Poster Abstract Presentations at Professional Meetings, Conferences, etc.

1. Takamura K, Dalton, J.C., **Karachunski P.I**. 2016. Congenital fiber type disproportion myopathy and novel compound heterozygous mutations in RYR1 gene. Next generation sequencing-A first line diagnostic tool for congenital myopathy. International World Muscle Society Congress. Granada, Spain
2. Petryk A., Polgreen L.E., Marsh J.E., Lowe D., Hodges J., **Karachunski P.I**. 2016. Tolerability and feasibility of whole body vibration and its effects on muscle function and bone health in patients with dystrophinopathy. European Society for Paediatric Endocrinology. Paris, France
3. **Karachunski P.I**., Marsh, J.E., Dalton, J.C. 2015. Muscle ultrasound in Duchene muscular dystrophy: Useful tool to monitor progression of early disease. International World Muscle Society Congress. Brighton, England, UK
4. **Karachunski P.I**., Adil, M.M. 2013. Respiratory insufficiency and cardiomyopathy in boys with hereditary muscular dystrophy. Comparative analysis using HCUP Kids Inpatient Database. MDA Scientific Conference. Washington DC, USA
5. **Karachunski P.I**., Takamura, K., Thyagarajan, B. Beckman, K., Onsongo, G., Silverstein, K., Bower, M. 2013. Efficacy of a targeted next generation panel as a 2nd tier diagnostic tool for neuromuscular disease of unknown etiology. MDA Scientific Conference. Washington DC, USA.
6. **Karachunski P.I**., Clark B and Dalton J. 2011. Syndrome of pontobulbar palsy with sensorineural deafness (Brown-Vialetto-Van Laere (BVVL) Syndrome).
7. **Karachunski P.I**., Margolis, M., Dalton J., and Day, J.W. 2009. LGMD 21: Response to Prednisone in twin boys. (Abstract) American Academy of Neurology annual symposium. Seat t le, USA.
8. **Karachunski P.I**., Shapiro E., Clark B. Distribution of the neuronal storage material in the CNS of children with mucopolysaccharidosis type I. 2004. (Abstract) WORLD symposium on lysosomal storage diseases. Minneapolis.
9. **Karachunski P.I**., Ostlie N., Okita D. K. and Conti-Fine B.M. November, 1998. Interleukine-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. (Abstract) International Myasthenia Gravis Workshop. Maysor, India.

10. Wang Z-Y. , **Karachunski P.I**., Howard Jr., J.F., and Conti- Fine B.M. November, 1998. Myasthenia in SCID mice engrafted with blood lymphocytes from myasthenia gravis patients Role of CD4 + and CD8+ cells. (Abstract) International Myasthenia Gravis Workshop. Maysor, India.
11. **Karachunski P.I**., Ostlie N., Okita D. K. and Conti-Fine B .M. October, 1998. IL- 4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. (Abstract) Montreal, Canada. Annual Scientific Session of the Myasthenia Gravis Foundation of America.
12. **Karachunski P.I**., Ostlie N., Okita D. K. and Conti-Fine B .M. October, 1998. CD4+ cells from C5781/6 mice treated nasally with acetylcholine receptor peptides protects IL-4 deficient mice from experimental myasthenia gravis. (Abstract) Montreal, Canada. Annual Scientific Session of the Myasthenia Gravis Foundation of America.
13. **Karachunski P.I**. , Ostlie N., Lei 5 ., Okita D., Lindstrom J .M. and Conti-Fine B.M. May 199. Immunization with high doses of acetylcholine receptor overcomes resistance to Experimental Autoimmune Myasthenia Gravis bm12 mice. (Abstract) Santa Monica, CA U.S.A. IXth International Conference on Myasthenia Gravis and Related Disorders.
14. **Karachunski P.I**., Ostlie N. , Okita D. K. and Conti-Fine B. M. May 1997. Prevention of Experimental Autoimmune Myasthenia receptor T epitope sequences. (Abstract) Santa Monica, CA U.S.A. IXth International Conference on Myasthenia Gravis and Related Disorders.
15. Raju R., Zhan W-Z., **Karachunski P.I**., Sieck G.C., Conti-Fine B.M. and David C. S . May 1997. Susceptibility of HLA DQ and DR transgenic mice to experimental autoimmune myasthenia gravis (EAMG). (Abstract) Santa Monica, CA U.S.A. IXth International Conference on Myasthenia Gravis and Related Disorders.
16. Bellone M., Ostlie N., **Karachunski P.I**., Lei S., and Conti-Tronconi B.M. 1992. Epitopi criptici sul receptore nicotinico dell ' acetilcolina sono riconsciuti da linfociti B e T CD4+auto reattivi. XII congresso della societa ' italiana di immunologia e immunopthologia.

INVITED LECTURES

National and International Lectures provided on request

Local Lectures

"Inflammatory Myopathy" Guest Speaker, MDA Neuromuscular Family Symposium	10/2016
Muscular Dystrophes, Part I - Resident Lecture	12/2014
"Clinical Updates in MD" Guest Speaker, MDA Adult Networking Group	01/2014
"Ask the Doctors Q & A" Guest Speaker, MDA Neuromuscular Family Symposium	10/2013
"Overview and Update of MG and its Treatments", Keynote Speaker, Myasthenia Gravis (MG) 40th Annual Meeting, Shoreview, MN	09/2012
Bone Health in MD, MD Center Seminar Series lecture co-presented with Dr. Dawn Lowe, University of Minnesota	03/2012
"Myasthenia Gravis updates and treatments", presenter, Myasthenia Gravis (MG) Annual Meeting, Shoreview, MN	09/2010
"Overview and treatments in Guillain-Barré syndrome / CIDP", Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Annual Conference, St. Paul, MN	09/2010

TEACHING AND CURRICULUM DEVELOPMENT

University of Minnesota *Use reverse chronological order – present to past – in each section.*
Course/Lecture List

STUDENT TEACHING:

Muscular dystrophy: clinical aspects, Biochemistry 5444 02/2014
Graduate Student Number: 12 University of Minnesota, Twin Cities Campus

Muscular dystrophy: clinical aspects, Biochemistry 5444 02/2013
Graduate Student Number: 20 University of Minnesota, Twin Cities Campus
Muscular dystrophy: clinical aspects", Biochemistry 5444 02/2012
Graduate Student Number: 6 University of Minnesota, Twin Cities Campus

RESIDENT TEACHING:

Neuromuscular Friday Lectures, Muscular Dystrophies, University of Minnesota 09/2016
Friday School Pediatric Neurology Subdirector Invitation, University of Minnesota 05/2015
PM&R Resident Lecture, University of Minnesota 05/2015
Neurology Resident Lecture, MD Part 1, University of Minnesota 12/2014
PM&R Resident Lecture, University of Minnesota 05/2013
Neurology Resident Lecture, RITE Review, University of Minnesota 11/2012
Neurology Resident Lecture, Nerve and Muscle Pathology, University of Minnesota 10/2012
PM&R Resident Lecture, University of Minnesota 06/2012
PM&R Resident Lecture, University of Minnesota 04/2012

FELLOWSHIP TEACHING:

Neuromuscular Medicine Clinical Competency Committee Meeting, Participating Faculty, University of Minnesota 01/2015
Pediatric Neuropsychology Fellowship Program, Participating Faculty, University of Minnesota 02/2013
Pediatric Rheumatology Fellowship Program, Participating Faculty, University of Minnesota 01/2013
Child Psychiatry Fellowship, Participating Faculty, University of Minnesota 11/2012

TEACHING CONFERENCES:

"Past, Current and Future in Management of Muscular Dystrophies. Duchenne Muscular Dystrophy as a Paradigm", Department of Pediatrics Grand Rounds, University of Minnesota 2016
"Identifying Neonatal Seizures and Treatment Modalities Before, During and After Transport". 2nd Annual NICU Transport Conference: Care of the Neurologically Fragile Infant. MHealth, Masonic Children's Hospital 2015
MDA Muscle Summit, Panel expert, "LGMD Research Updates", and "IBM Research Updates" 2015
"Myasthenia Gravis", Department of Neurology Grand Rounds, 2011

ADVISING AND MENTORING

Undergraduate Student Activities

Undergraduate advising
- Raviro Machaka 9/2016
- Ruby Carlson 5/2016
- Arshia Arora 7/2015 & 5/2016
- Nancy Abdelrahman 5/2015
- Hennelie Hawes 4/2015
- Anja Cucak 3/2015

Graduate Student Activities

Master's Student Advisees

Kenji Takamura 2015

Doctoral Students Advised (Academic advising for all or part of graduate student's program)

Joyce Trost 2016-Present
Irina Kharisova 1/2016 & 8/2016
Ava Yun Lin 2012

Residents Supervised

Sarah Meyer 2014

MEDICAL STUDENTS:

Mayank Verma 2016-Present
Andrea Johnson 2014

CLINIC OBSERVERS:

Judith Pazorora, MD 3/2016
Eli Kelley 3/2016
John Asher Jenkins 12/2015
David Kraus 10/2015
Samuel Hochberger 9/2015
Lucas Simmons 6/2014

Visiting Scholars Hosted

Carsten G. Bönnemann, M.D. 02/04-05/2016
National Institute of Neurological Disorders and Stroke (NINDS)
Minnesota Congenital Muscle Disease Traveling Local Clinic
Michael Lawlor, M.D. 02/26-27/2015
Neuromuscular Laboratory, Medical College of Wisconsin
"Emerging Treatments in X-linked Myotublar Myopahty and Nemaline Myopathy"
Michael Shy, M.D. 01/31-2/1/2014
University of Iowa Carver College of Medicine
"An Approach to Diagnosing and Treating Inherited Neuropathies."
Carsten G. Bönnemann, M.D. 02/04-05/2016
National Institute of Neurological Disorders and Stroke (NINDS) 10/30-11/1/2013
"Congenital Muscular Dystrophies: Muscle Meets its Matrix"
Valerie Cwik, M.D. 03/29/2013
Executive Vice President &Chief Medical and Scientific Officer for MDA
"Clinical Trial Readiness for Neuromuscular Diseases: What Do We Need?"
Katherine Mathews, M.D. 05/30-31/2012
University of IA
"Congenital Muscular Dystrophies: Recognition and Diagnosis"

CLINICAL SERVICE

Clinical Leadership Accomplishments

MDA Clinical Director, Minnesota Regional 2011-present

Clinical Service Responsibilities

University of Minnesota Medical Center 2015-present
20 weeks per year Pediatric Neurology in-patient service
11 weeks per year EEG interpretation and report for in-patient and out-patient services

176 half-day outpatient weekly clinics per year

24 weeks per year of inpatient on-service 2014
104 half-day outpatient weekly clinics per year

32 weeks per year of inpatient on-service 2013
104 half-day outpatient weekly clinics per year

Gillette Children's Specialty Healthcare 2008-2015
2-3 half-day outpatient clinics per week

PROFESSIONAL SERVICE AND PUBLIC OUTREACH

Service To The Discipline/Profession/Interdisciplinary Area

Physician Advisory Panel at Medica 2017-Present
Minneapolis, MN

Minnesota Department of Health (MDH) Advisory Board for new born Screening 2016-present
St. Paul, MN

Editorships/Journal Reviewer Experience

Reviewer Journal of Pediatrics 2017-Present
Reviewer Research and Clinical grants 2015-present

Professional Service

Minnesota Congenital Muscle Disease Traveling Local Clinics (CMD TLC) 2013, 2016

Community Outreach Activities

Mount Olive Lutheran Church Outreach, volunteer physician, consultant and community liaison. 10 days a year dedicated to setting up clinics and mission hospital dedicated to care and treatment of DMD patients in Odzi, Zimbabwe. 2014-present

Consultant Rock the Pavement, volunteer physician and runner for annual event to raise funds for muscular dystrophy research 2013-present

MDA Neuromuscular Family Symposium, co-organizer and consultant for annual symposium catering to families affected by neuromuscular diseases. 2012-present

Lab Day, co-organizer for one day event each year where research, clinical and community efforts provide a hands on experience open to the public about muscular dystrophies. 2010-present

Paul and Sheila Wellstone Muscular Dystrophy Center Family Camp, co-organizer for annual weekend event which provides an opportunity for families living with muscular dystrophy support and family to experience together. 2010-present

Greg Marzolf Jr. Symposium, co-organizer for annual symposium featuring renowned speaker in muscle research and awards to undergraduates who exemplify interest in future muscle research. 2010-present

Cause to Cook, event volunteer for annual gala dedicated to funding Education and research programs benefitting children and families suffering from muscular dystrophy 2010-present

MDA Walk, MN Chapter, team leader for annual event to raise awareness on muscular dystrophies 2010-present

MDA Summer Camp, MN Chapter, volunteer physician 1 week out of each summer to children with neuromuscular diseases. 2009-present